10 terminated. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 10 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2 - Metastatic Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 87 | 2021-03-05 | 2025-05-08 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer CUDC-907 - Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2016-12-22 | 2018-12-21 |
| A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Lenvatinib 24 mg - Thyroid Carcinoma, Anaplastic | Phase 2 | Terminated | Eisai Inc. | 34 | 2016-07-07 | 2019-10-15 |
| Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Bevacizumab - Thyroid Neoplasms, Carcinoma | Phase 2 | Terminated | Region Skane | 15 | 2008-04-01 | 2018-08-28 |
| A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel CS-7017, Paclitaxel - Anaplastic Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 19 | 2008-01-01 | 2020-09-16 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer CA4P, paclitaxel, carboplatin - Anaplastic Thyroid Cancer | Phase 2 / Phase 3 | Terminated | Mateon Therapeutics | 80 | 2007-08-01 | 2014-06-09 |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer sorafenib tosylate - Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2005-06-01 | 2018-01-19 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer sorafenib tosylate, laboratory biomarker analysis, pharmacological study - Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-10-01 | 2014-01-16 |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Imatinib - Thyroid Cancer | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 11 | 2004-02-01 | 2014-04-21 |
| Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer filgrastim, pegfilgrastim, cisplatin - Head and Neck Cancer | Phase 1 / Phase 2 | Terminated | Case Comprehensive Cancer Center | 4 | 2003-11-01 | 2010-06-11 |
Thyroid Neoplasms (6) · Neoplasm Metastasis (2) · Adenocarcinoma, Follicular (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Thyroid Cancer, Papillary (1)
Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Carcinoma (9) · Neoplasms (9) · Neoplasms by Site (8) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Head and Neck Neoplasms (6) · Thyroid Diseases (6) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Bronchial Neoplasms (1)
Doxorubicin (2) · Paclitaxel (2) · Sorafenib (2) · fosbretabulin (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Bevacizumab (1) · CUDC-907 (1) · Carboplatin (1) · Cisplatin (1) · Filgrastim (1) · Fluorodeoxyglucose F18 (1) · Imatinib Mesylate (1) · Magnetic Resonance Spectroscopy (1) · Radiotherapy (1) · combretastatin (1)
National Cancer Institute (NCI) (3) · Case Comprehensive Cancer Center (1) · Daiichi Sankyo (1) · Eisai Inc. (1) · Hutchmed (1) · Mateon Therapeutics (1) · Region Skane (1) · University of Michigan Rogel Cancer Center (1)
United States (9) · Italy (2) · United Kingdom (2) · Australia (1) · Belarus (1) · Bulgaria (1) · Egypt (1) · France (1) · India (1) · Israel (1) · Poland (1) · Romania (1) · Russia (1) · Sweden (1) · Ukraine (1)
Francis P Worden, MD (1) · Jan Tennvall, MD, PhD (1) · Julie A. Sosa, MD, FACS (1) · Manisha Shah (1) · Naris Nilubol, M.D. (1) · Panayiotis Savvides (1) · Panayiotis Savvides, MD (1) · William Schelman, MD (1)
PMID 23113752, PMID 27240885, PMID 33961488, PMID 37816266
2015 (1), N01CM62206 (1), N01CM62207 (1), P30CA016058 (1), P30CA043703 (1), U01CA062502 (1), U01CA076576 (1)